This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    A phase 3, double-masked, randomized, controlled study to evaluate the safety and efficacy of KPI-121 1.0% ophthalmic suspension in subjects with post-surgical inflammation and pain
Previous Study | Return to List | Next Study

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Kala Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT02793817
First received: June 3, 2016
Last updated: April 25, 2017
Last verified: March 2017
  Purpose
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.

Condition Intervention Phase
Post Surgical Ocular Inflammation and Pain Drug: KPI-121 1% Ophthalmic Suspension dosed BID Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain

Resource links provided by NLM:


Further study details as provided by Kala Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Proportion of study eyes with complete resolution of anterior chamber cells (cell score = 0) in the study eye [ Time Frame: Visit 5 (Day 8) maintained through Visit 6 (Day 15) ]
  • Proportion of study eyes with complete resolution of ocular pain (grade = 0) in the study eye [ Time Frame: Visit 5 (Day 8) maintained through Visit 6 (Day 15)] ]

Estimated Enrollment: 520
Study Start Date: June 2016
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: KPI-121 1.0% Ophthalmic Suspension
dosed BID
Drug: KPI-121 1% Ophthalmic Suspension dosed BID
Other Name: Loteprednol etabonate
Placebo Comparator: Vehicle of KPI-121 Ophthalmic Suspension
dosed BID
Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Other Name: Placebo

Detailed Description:
This is a Phase III, multicenter, double-masked, randomized, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of KPI-121 1.0% ophthalmic suspension versus placebo in subjects who require treatment of postoperative anterior ocular inflammation.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Candidates for routine, uncomplicated cataract surgery

In Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of at least 20/200 in study eye.

Exclusion Criteria:

  • Known hypersensitivity/contraindication to study product(s) or components.
  • History of glaucoma, intraocular pressure (IOP) >21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.
  • Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening or 18 days following surgery.
  • In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02793817

  Show 35 Study Locations
Sponsors and Collaborators
Kala Pharmaceuticals, Inc.
  More Information

Responsible Party: Kala Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02793817     History of Changes
Other Study ID Numbers: KPI-121-C-005
Study First Received: June 3, 2016
Last Updated: April 25, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Kala Pharmaceuticals, Inc.:
postsurgical
postoperative
ocular
cataract
inflammation
pain
corticosteroid

Additional relevant MeSH terms:
Inflammation
Pathologic Processes
Loteprednol Etabonate
Anti-Allergic Agents

ClinicalTrials.gov processed this record on June 23, 2017